Short and long latency afferent inhibition in Parkinson's disease.

Interactions between inhibitory and excitatory circuits in the human motor cortex. Exp Brain Res (2003) 2.42

Increased motor cortical facilitation and decreased inhibition in Parkinson disease. Neurology (2013) 1.47

Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain (2012) 1.31

Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans. J Physiol (2005) 1.17

Interactions between long latency afferent inhibition and interhemispheric inhibitions in the human motor cortex. J Physiol (2005) 1.05

Modulation of human corticospinal excitability by paired associative stimulation. Front Hum Neurosci (2013) 1.02

Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J Neurol Neurosurg Psychiatry (2005) 0.95

Short-latency afferent inhibition during selective finger movement. Exp Brain Res (2005) 0.92

Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain (2009) 0.92

Short-latency afferent inhibition modulation during finger movement. PLoS One (2013) 0.90

Motor cortex inhibitory circuits in dementia with Lewy bodies and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 0.89

Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability. J Neural Transm (Vienna) (2011) 0.89

Sensorimotor integration to cutaneous afferents in humans: the effect of the size of the receptive field. Exp Brain Res (2005) 0.88

Interactions between short latency afferent inhibition and long interval intracortical inhibition. Exp Brain Res (2009) 0.86

Motor cortical plasticity in Parkinson's disease. Front Neurol (2013) 0.86

Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study. Exp Brain Res (2005) 0.84

Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network. Front Neurol (2014) 0.84

Slow (1 Hz) repetitive transcranial magnetic stimulation (rTMS) induces a sustained change in cortical excitability in patients with Parkinson's disease. Clin Neurophysiol (2010) 0.84

Short latency afferent inhibition differs among the subtypes of mild cognitive impairment. J Neural Transm (Vienna) (2011) 0.83

Abnormal short latency afferent inhibition in early Alzheimer's disease: a transcranial magnetic demonstration. J Neural Transm (Vienna) (2008) 0.83

A Review of Transcranial Magnetic Stimulation and Multimodal Neuroimaging to Characterize Post-Stroke Neuroplasticity. Front Neurol (2015) 0.83

Controllable pulse parameter transcranial magnetic stimulator with enhanced circuit topology and pulse shaping. J Neural Eng (2014) 0.83

Sensorimotor adaptation of speech in Parkinson's disease. Mov Disord (2013) 0.83

Modulation of short-latency afferent inhibition depends on digit and task-relevance. PLoS One (2014) 0.82

Normal or enhanced short-latency afferent inhibition in Parkinson's disease? Brain (2004) 0.82

Plasticity of cortical inhibition in dystonia is impaired after motor learning and paired-associative stimulation. Eur J Neurosci (2012) 0.82

Non-dominant hand movement facilitates the frontal N30 somatosensory evoked potential. BMC Neurosci (2010) 0.81

Induction of motor associative plasticity in the posterior parietal cortex-primary motor network. Cereb Cortex (2013) 0.81

The influence of sensory afferent input on local motor cortical excitatory circuitry in humans. J Physiol (2015) 0.80

Hemispheric asymmetry and somatotopy of afferent inhibition in healthy humans. Exp Brain Res (2005) 0.80

Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients. Neuropsychopharmacology (2014) 0.80

Paired-pulse inhibition in the auditory cortex in Parkinson's disease and its dependence on clinical characteristics of the patients. Parkinsons Dis (2010) 0.80

Modulation of short-latency intracortical inhibition in human primary motor cortex during synchronised versus syncopated finger movements. Exp Brain Res (2005) 0.80

Cortical excitability and neurology: insights into the pathophysiology. Funct Neurol (2013) 0.79

Long-latency afferent inhibition during phasic finger movement in focal hand dystonia. Exp Brain Res (2008) 0.79

Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases. Transl Neurodegener (2015) 0.79

Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics (2016) 0.79

Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL. J Neural Transm (Vienna) (2014) 0.78

Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. Neurology (2015) 0.78

Treatment and physiology in Parkinson's disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action. Curr Neurol Neurosci Rep (2014) 0.77

Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature. Parkinsonism Relat Disord (2013) 0.77

Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals. Front Aging Neurosci (2014) 0.77

Short-latency afferent inhibition in patients with Parkinson's disease and freezing of gait. J Neural Transm (Vienna) (2015) 0.76

Neurophysiological biomarkers for Lewy body dementias. Clin Neurophysiol (2015) 0.76

Functional evaluation of central cholinergic circuits in patients with Parkinson's disease and REM sleep behavior disorder: a TMS study. J Neural Transm (Vienna) (2012) 0.76

Intracortical circuits, sensorimotor integration and plasticity in human motor cortical projections to muscles of the lower face. J Physiol (2013) 0.76

Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study. J Neural Transm (Vienna) (2011) 0.76

Cortical Plasticity in Depression. ASN Neuro (2017) 0.76

Reduced Prefrontal Short-Latency Afferent Inhibition in Older Adults and Its Relation to Executive Function: A TMS-EEG Study. Front Aging Neurosci (2017) 0.76

Short-latency afferent inhibition determined by the sensory afferent volley. J Neurophysiol (2016) 0.75

Vascular Cognitive Impairment through the Looking Glass of Transcranial Magnetic Stimulation. Behav Neurol (2017) 0.75

Sensorimotor integration in patients with parkinsonian type multisystem atrophy. J Neurol (2005) 0.75

No relation between afferent facilitation induced by digital nerve stimulation and the latency of cutaneomuscular reflexes and somatosensory evoked magnetic fields. Front Hum Neurosci (2014) 0.75

Aristotle's illusion in Parkinson's disease: evidence for normal interdigit tactile perception. PLoS One (2014) 0.75

Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients. J Neural Transm (Vienna) (2012) 0.75

Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal. J Neural Transm (Vienna) (2017) 0.75

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76

Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77

From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77

Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56

Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet (2012) 4.41

Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86

Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66

Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52

Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22

Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15

Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10

Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07

Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79

Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67

A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64

Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53

Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46

Surgical management of tethered cord syndrome in adults: indications, techniques, and long-term outcomes in 60 patients. J Neurosurg Spine (2006) 2.43

Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40

MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res (2008) 2.38

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32

Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23

Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21

Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19

Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18

Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18

Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11

Contralesional repetitive transcranial magnetic stimulation for chronic hemiparesis in subcortical paediatric stroke: a randomised trial. Lancet Neurol (2008) 2.10

Multimodal imaging of brain reorganization in motor areas of the contralesional hemisphere of well recovered patients after capsular stroke. Brain (2005) 2.03

Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01

Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00

Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99

A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98

The mechanisms of interhemispheric inhibition in the human motor cortex. J Physiol (2002) 1.92

Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86

Constraint-induced therapy in stroke: magnetic-stimulation motor maps and cerebral activation. Neurorehabil Neural Repair (2003) 1.83

Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82

Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82

Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81

Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81

Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79

Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77

Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73

Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70

Effect of low-frequency repetitive transcranial magnetic stimulation on interhemispheric inhibition. J Neurophysiol (2005) 1.70

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood (2012) 1.67

Deep brain stimulation for Parkinson's disease: disrupting the disruption. Lancet Neurol (2002) 1.67

Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66

Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65

Absence of integrin αvβ3 enhances vascular leak in mice by inhibiting endothelial cortical actin formation. Am J Respir Crit Care Med (2012) 1.64

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63

Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63

Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63

Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63

Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62

Exploring the connectivity between the cerebellum and motor cortex in humans. J Physiol (2004) 1.60

Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59

Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58

Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54

Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54

Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53

Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53

Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51

N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci (2012) 1.49

Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep (2002) 1.48

Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47

Myoclonus. Continuum (Minneap Minn) (2013) 1.47

Increased motor cortical facilitation and decreased inhibition in Parkinson disease. Neurology (2013) 1.47

Somatosensory evoked potentials recorded from the human pedunculopontine nucleus region. Mov Disord (2010) 1.46

Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46

Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46

Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45

Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45

Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45

Effective treatment of mouse sepsis with an inhibitory antibody targeting integrin αvβ5. Crit Care Med (2013) 1.44

The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43

Clinical Management Updates in Mantle Cell Lymphoma. Oncology (Williston Park) (2016) 1.43

Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42

Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42

Engraftment is optimal when myoblasts are transplanted early: the role of hepatocyte growth factor. Ann Thorac Surg (2010) 1.42

α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42